Gastric Cancer and Intestinal Metaplasia: Differential Metabolic Landscapes and New Pathways to Diagnosis

Gastric cancer (GC) is the fifth most common cause of cancer-related death worldwide. Early detection is crucial for improving survival rates and treatment outcomes. However, accurate GC-specific biomarkers remain unknown. This study aimed to identify the metabolic differences between intestinal met...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2024-09, Vol.25 (17), p.9509
Main Authors: Choi, Seong Ji, Choi, Hyuk Soon, Kim, Hyunil, Lee, Jae Min, Kim, Seung Han, Yoon, Jai Hoon, Keum, Bora, Kim, Hyo Jung, Chun, Hoon Jai, Park, Youngja H
Format: Article
Language:English
Subjects:
Aged
Antigens
Biomarkers
Biomarkers, Tumor - metabolism
Biosynthesis
Female
Gastric cancer
Humans
Male
Medical prognosis
Medical screening
Metabolic Networks and Pathways
Metabolism
Metabolites
Metabolome
Metabolomics - methods
Metaplasia - metabolism
Metaplasia - pathology
Middle Aged
Patients
Principal components analysis
Steroids
Stomach Neoplasms - diagnosis
Stomach Neoplasms - metabolism
Stomach Neoplasms - pathology
Tandem Mass Spectrometry - methods
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gastric cancer (GC) is the fifth most common cause of cancer-related death worldwide. Early detection is crucial for improving survival rates and treatment outcomes. However, accurate GC-specific biomarkers remain unknown. This study aimed to identify the metabolic differences between intestinal metaplasia (IM) and GC to determine the pathways involved in GC. A metabolic analysis of IM and tissue samples from 37 patients with GC was conducted using ultra-performance liquid chromatography with tandem mass spectrometry. Overall, 665 and 278 significant features were identified in the aqueous and 278 organic phases, respectively, using false discovery rate analysis, which controls the expected proportion of false positives among the significant results. sPLS-DA revealed a clear separation between IM and GC samples. Steroid hormone biosynthesis, tryptophan metabolism, purine metabolism, and arginine and proline metabolism were the most significantly altered pathways. The intensity of 11 metabolites, including N1, N2-diacetylspermine, creatine riboside, and N-formylkynurenine, showed significant elevation in more advanced GC. Based on pathway enrichment analysis and cancer stage-specific alterations, we identified six potential candidates as diagnostic biomarkers: aldosterone, N-formylkynurenine, guanosine triphosphate, arginine, S-adenosylmethioninamine, and creatine riboside. These metabolic differences between IM and GC provide valuable insights into gastric carcinogenesis. Further validation is needed to develop noninvasive diagnostic tools and targeted therapies to improve the outcomes of patients with GC.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms25179509